To investigate the effect of Maillard reaction (MR) and gastrointestinal digestion (GID) on the antihyperuricemic activity of tuna protein hydrolysate (TPH), hyperuricemia rats were treated with TPH, its MR products (TPH-M) and gastrointestinal digesta (TPH-D) in this work. Although the XO inhibitory activity of TPH-M was higher than TPH, TPH-M exhibited even lower serum-uric-acid-lowering activity than TPH. Additionally, there was no significant (P < 0.05) difference observed in the inhibition of XO activity in vitro and antihyperuricemic activity of TPH and TPH-D, indicated that the antihyperuricemic activity of TPH would not decrease after GID. Additionally, TPH, TPH-M and TPH-D could effectively inhibit XO activity and downregulate XO mRNA expression in vivo, suggesting the mechanisms of antihyperuricemic effect was related to XO inhibitory activity and XO mRNA expression. As a whole, TPH could be a useful functional ingredient against hyperuricemia.
Introduction
Uric acid or its monoanion urate in human body is a selective antioxidant that can effectively scavenge free radicals produced during metabolism, especially those involving reaction with hydroxyl radicals and hypochlorous acid (Ridi & Tallima, 2017) . However, excessive serum uric acid would lead to increased risk of some chronic diseases, such as hyperuricemia, which could induce gout (Richette & Bardin, 2009 ). The amount of hyperuricemia and gout patients is increasing in developed countries especially in America and Europe (Annemans et al., 2008; Zhu et al., 2011) . In addition, some epidemiological studies have pointed out the association between high serum uric acid level and hypertension (Feig, 2014) , metabolic syndrome (Yadav et al., 2015) and renal failure (Li et al., 2015) .
During the metabolism of purine in the human body, hypoxanthine is oxidised via xanthine to uric acid by xanthine oxidase (XO). At present, categories of drugs for treating hyperuricemia or acute gout major include mainly anti-inflammatory agents (e.g. naprosyn) (Perezruiz, 2009) or agents that can accelerate urate excretion (e.g. benzbromarone) or XO inhibitor (e.g. allopurinol) (Ohno et al., 2008; Tausche et al., 2009) . However, these chemical drugs are inherent side-effects, including kidney or liver dysfunction, muscle atrophy and malfunction of central nervous system. Thus, it is essential to investigate the novel substances which are safe and effective for hyperuricemia treatment.
Interestingly, some individual amino acids (Val, Trp) and tryptophan-containing peptides have been reported to exhibit negative effects on XO activity (Nongonierma & Fitzgerald, 2012; Nongonierma et al., 2013) . Besides, shark cartilage hydrolysate (Murota et al., 2014) and walnut protein hydrolysate (Li et al., 2018) showed antihyperuricemic activity after oral administration. Additionally, our previous study found that tuna protein hydrolysate (TPH) could effectively inhibit XO activity in vitro (Su et al., 2018) . It is reasonable to investigate the antihyperuricemic effect of TPH in oteracil potassium-induced hyperuricemia rats.
Proteins or large peptides would be further hydrolysed to short peptides or individual amino acids by pepsin and pancreatin from digestive tract, leading to change the bioactivity of original peptides. Murota et al. (2014) found that Ser-Pro-Pro-Tyr-Trp-Pro-Tyr exhibited significantly different antihyperuricemic activity after oral administration or intravenous injection. In addition, during food processing and storage, Maillard reaction occurs spontaneously mainly through the interaction between reducing sugars and amino groups. Except for colour and flavour, Maillard reaction could also influence the bioactivity of food system. The antioxidant activity of food system could be dramatically increased after Maillard reaction (Zhao et al., 2014) . Therefore, it is interesting to investigate the bioactivity changes of some peptides with potential therapeutic function in digestive tract and Maillard reaction.
In the present study, tuna protein hydrolysate (TPH), its in vitro digesta (TPH-D) hydrolysed by pepsin and pancreatin, and Maillard reaction products (TPH-M) derived from TPH and xylose were obtained. In vitro xanthine oxidase (XO) inhibitory activity and serum-uric-acid-lowering activity of TPH, TPH-D and TPH-M were evaluated to investigate the influence of GI digestion and Maillard reaction on the bioactivity of TPH. The XO activity and expression of XO mRNA of oteracil potassium-induced hyperuricemia rats treated by TPH, TPH-D and TPH-M were further measured to study the mechanism of antihyperuricemic effect of TPH and its derived products.
Materials and methods

Materials and chemicals
The frozen tuna was purchased from Nansha aquatic product market (Guangzhou, China), and the head, tail, fins, organs and skin of the tuna were removed, the meat was collected and ground into mince. Then the mince was stored in a sealed polyethylene bag at À18°C until use.
Uric Acid, allopurinol, xanthine and xanthine oxidase was purchased from Sigma-Aldrich (Shanghai, China), Alcalase 2.4 L (170 000 U mL À1 ) was obtained from Novozymes (Bagsvaerd, Denmark). Pepsin (40 000 U g À1 ) and pancreatin (240 000 U g À1 ) were obtained from Guangzhou Geneshun Biotech Ltd (Guangzhou, China). PCR primer was from Generay Biotechnology Company (Shanghai, China). PUC18 DNA/Mspl marker and other assay kits were from Tiangen Biochemical Technology Company (Beijing, China). Other reagents were of analytical grade.
Preparation of tuna protein hydrolysate (TPH), in vitro digesta (TPH-D) and Maillard reaction products (TPH-M)
Fifty grams of tuna mince were mixed with 100 g of deionised water, and subject to hydrolysis catalysed by 0.25% Alcalase 2.4L (w/w) for 6 h at 55°C and pH 7.0. The enzymatic hydrolysis was terminated through inactivating the enzyme in boiling water for 15 min. The obtained hydrolysate was centrifuged in a GL-21M refrigerated centrifuge (Xiangyi Instrument Co. Ltd., Changsha, China) at 8000 g for 20 min at 4°C. The supernatant was collected and lyophilised (R2L-100KPS, Kyowa Vacuum Engineering, Tokyo, Japan) and stored at À18°C till use.
TPH-D was prepared following the method of (Zhu et al., 2008) . Additionally, TPH-M was prepared following the method in the previous study (Zhao et al., 2014) with slight modifications, the lyophilised TPH (10 g) and xylose (1 g) were dissolved separately in deionised water (100 mL), before being mixed together and heated to 110°C for 30 min (to obtain TPH-M). The TPH-M was cooled immediately in an ice-water bath. All the samples (TPH, TPH-D and TPH-M) were lyophilised and stored at À18°C till use.
Xanthine oxidase (XO) inhibitory activity
The XO inhibition assay was carried out following the method of Murota et al. (2014) with slight modifications. Fifty microlitre xanthine (6 mmol L À1 ), 50 lL XO (15 mU mL À1 ), 200 lL TPH, TPH-M or TPH-D were mixed in the wells of a 96-well plate, respectively. All the materials were dissolved in 50 mM Tris-HCl buffer at pH 7.5. Each sample of interest was analysed in triplicate. The plate was incubated for 10 min at 25°C in the Varioskan Flash Spectral Scan Multimode Plate Reader (Thermo Fisher Scientific, Waltham, MA, USA), and the reaction was terminated by adding 50 lL of HCl (2 M). The absorbance was recorded at 290 nm. Tris-HCl buffer was used as the negative control, respectively. The XO inhibition was determined by the remaining activity against the negative control.
The inhibition of XO activity (%) = 1 À (A s ÀA s0 )/ (A c ÀA c0 ) 9 100%, where A c0 is the absorbance before reaction while A c means the absorbance of control without the sample, and A s0 is the absorbance before reaction while A s is the absorbance after reaction in presence of the sample.
The amino acid composition analysis
The amino acid profiles of TPH, TPH-M and TPH-D were determined based on the method of You et al. (2010) using an A300 auto amino acid analyser (Membra Pure, Bodenheim, Germany). Total amino acid composition determination was performed after the hydrolysis at 110°C for 24 h with 6 M HCl prior to derivatisation with ninhydrin. Free amino acid composition of the test samples was determined based on the free amino acids in the supernatant generated through centrifugation (11 180 g and 4°C for 10 min) of the precipitate from the mixture (mixing time 1 h) of 15% sulphosalicylic acid (1 mL) and test samples (4 mL). Seventeen amino acid standards were used as external standards.
Animals experiments
The animal use and protocol were approved by Guangdong Provincial Laboratory Animal Public Service Center (Permit Number: SYXK (yue) 2013-0085). Seventy-two male rats (weighed 200 AE 20 g) were obtained from School of Medical Information Engineering Laboratory (Permit Number: SYXK (yue) 2012-0117), housed under conditions of 25°C with a 12 h light-dark cycle and standard diet and water, randomly divided into normal control group (twelve rats) and model group (sixty rats). The model group rats were intragastric administrated with potassium oxonate (daily dose: 2 g kg À1 body weight) for 7 days. The successfully modelled rats were further randomly divided into five subgroups for the following treatment for 30 day: (1-3) three subgroups were orally treated with TPH, TPH-M and TPH-D, respectively, at a dose of 80 mg kg À1 body weight; (4) the allopurinol group was fed with allopurinol at a dose of 25 mg kg À1 body weight; (5) the model control group (administered the same volume of distilled water).
Fifty minutes after the last administration, the rats were anesthetised via intraperitoneal injection of 3% sodium pentobarbital (30 mg kg À1 body weight), and their blood was taken from the abdominal aorta (5 mL), then the liver was removed and (1 g) was homogenised with double distilled water (9 g). Finally, 100 lL tissue homogenate was determined according to the kit instructions. The serum uric acid, the xanthine oxidase (XO) activity of the serum and liver tissue were determined. In a separate experiment, the XO mRNA in liver was extracted following the published standard protocols (Gao et al., 2010) and amplified by gradient cycler (Mastercycler Gradient, Eppendorf, Germany). The expression of the XO mRNA in liver was determined by RT-PCR using the LightCycler480 fluorescence ration PCR instrument (Roche Diagnostics, Basel, Switzerland).
Statistical analysis
At least two independent trials were performed for each type of experiment. Each analysis was conducted in triplicate, and the data were presented as 'mean AE standard deviation'. The results obtained were subject to one-way analysis of variance (ANOVA). Duncan's new multiple range test was performed to determine the significant difference between samples at the 95% confidence interval using SPSS 19.0 software (SPSS Inc., Chicago, IL, USA).
Results and discussion
Effect of in vitro digestion and Maillard reaction on amino acids composition Some literatures had reported that some peptides of protein hydrolysates would be degraded into shorter peptides or amino acids by gastrointestinal digestion in vitro (Zhu et al., 2008) , and Maillard reaction could also change the composition of peptides and amino acids (Zhao et al., 2013) . In this study, free amino acids contents of TPH, TPH-D and TPH-M were evaluated and the results are showed in Table 1 .
The free amino acids content in TPH-D (116.77 mg g À1 ) was dramatically higher than that in TPH (38.68 mg g À1 ), indicating further hydrolysis of TPH occurred during in vitro digestion. In particular, some amino acids (Tyr, Phe, Val, Lys, Leu and Arg) in TPH-D increased above three times as much as those in TPH, owing to pepsin could preferably cleave hydrophobic and aromatic amino acids, while trypsin would specially cleave the peptide bond between Lys and Arg. Similar results were reported by You et al. (2010) , who confirmed the contents of Leu and Phe increased sharply after an in vitro digestion. Furthermore, free AAs in TPH-D only accounted for 12.79% of total AAs after the simulated gastrointestinal digestion, which mean more than 85% AAs presented in the final digesta were still peptide structures.
Adding xylose to TPH would induce Maillard reaction, resulting in free amino acid significant (P < 0.05) decrease (from 38.68 to 30.08 mg g À1 ) (Table 1) . And 22-28% reduction in Lys, Glu, Tyr, Phe and Arg content was observed, especially Lys had the greatest decrease (28.02%). The greatest reactivity of the basic amino acids and the high loss of hydrophobic amino acids detected in this study were in good accordance with former findings (Su et al., 2011; Karangwa et al., 2015) . Moreover, Lys was likely the most sensitive amino acid to Maillard reaction, which was in agreement with the results of Zhao et al.(2013) . In contrast, Val, Asp and Pro seemed to be the least reactive amino acids (only 19% loss). Our previous research (Su et al., 2011) have proved that Pro was stable as the xylose concentration increasing, being less reactive than the other amino acids.
Effect of in vitro digestion and Maillard reaction on the in vitro xanthine oxidase (XO) activity A dose-dependent manner with different increasing patterns was found in the plots of XO inhibitory activity versus trial sample concentration (from 0.5 to 5.0 mg mL À1 ) for TPH, TPH-D and TPH-M (Fig. 1) . Except for 3.0 mg mL À1 , TPH generally exhibited stronger XO inhibitory activity than TPH-D in all concentrations. From 0.5 to 2.5 mg mL À1 , stronger the inhibition of XO activity was observed in TPH, while TPH-M exhibited stronger one than TPH above 3.0 mg mL
À1
. For TPH, a plateau was achieved at 1.0-3.0 mg mL À1 , followed by a rise with increasing concentration. It indicated that peptides with XO inhibitory activity could be released from tuna intact proteins via enzymatic hydrolysis catalysed by Alcalase 2.4L. Meanwhile both in vitro digestion and Maillard reaction would change the special bioactivity of protein hydrolysate.
Minimal change (P > 0.05) in XO inhibition was observed after in vitro digestion, such a result suggested that the XO inhibitory peptide released from TPH by Alcalase 2.4L would likely resist further in vitro gastrointestinal digestion, possibly due to the factor that low molecular mass of these peptides resisted gastro-intestinal hydrolysis (Nongonierma & Fitzgerald, 2012) .
Maillard reaction could impart a considerable effect on the inhibition of XO activity, especially a sharp enhancement when the trial sample concentration was above 2.5 mg mL À1 . Since nitrogenous heterocycle complexes could inhibit XO activity through combining to the enzyme's active site (Cao et al., 2011) , the higher XO inhibitory activity of TPH-M is possibly due to the production of heterocycle generated by Maillard reaction. Moreover, the inhibitory activity of some Maillard reaction products on the oxidoreductases (e.g. peroxidase) was observed (Pitotti et al., 2010) . As a kind of oxidoreductases, XO might also be inhibited by Maillard reaction products.
Effect of TPH, TPH-D, TPH-M on the XO activity in serum and liver of rats
The GI tract is known to be a major barrier for the oral administration of bioactive components, and the bioactivity in vivo of peptides might change due to the fact that some peptides would be further digested by GI enzymes (Wang et al., 2016) . Therefore, it is necessary to evaluate the XO activity in serum and liver of hyperuricemia rats treated by TPH, TPH-D and TPH-M.
As Table 2 showed, treated by TPH, TPH-D and TPH-M could decrease significantly (P < 0.05) in vivo XO activity of oteracil potassium-induced hyperuricemia rats, except for XO activity in liver of rats treated by TPH-D. All the XO activities of model rats treated by TPH, TPH-D or TPH-M were higher than that by allopurinol but weaker than the rat in model group. Moreover, the XO activity decreased in the order of TPH > TPH-M % TPH-D for serum and TPH-D > TPH-M % TPH for liver. Overall, TPH-M had a stronger negative effect on the in vivo XO activity, which was in agreement with the trend found in in vitro experiments above.
Generally, the bioactive peptides may alter the potential bioactivity detected by in vitro assays due to virous factors. For in vivo trials, different peptides and coexisting substances could enter the blood through intestine by different routes, and the permeability of peptides is influenced by molecular weight, hydrophobicity and electrostatic repulsion (Yang et al., 2017) . Additionally, different XO inhibitory activities detected between in vivo and in vitro, and between the serum and liver samples, maybe due to the different optimal concentrations required for in vivo and in vitro trials, as well as variations in the condition of enzymes, the species used in testing and coexisting substances in the test sample (Mo et al., 2007) . Even due to the fact that part of peptides is normally hydrolysed by varied peptidases in the blood or cytoplasm.
Effect of TPH, TPH-D, TPH-M on XO mRNA expression in liver of rats
The pathogenesis of hyperuricemia is closely associated with elevated XO activity and mRNA expression. In this section, the effect of TPH, TPH-D and TPH-M treatments on XO mRNA expression to help understand the underlying mechanisms of their XO inhibitory properties. Figure 2a ,b clearly showed the dramatic up-regulation of XO mRNA expression in liver of hyperuricemia rats (i.e. model control group compared to normal control group), and the notable down-regulation of XO mRNA expression in TPH and TPH-M groups (i.e. decreased 26.18% and 41.36% compared to model control group, respectively) was observed. There was no statistically significant (P > 0.05) difference in XO mRNA expression between the alloputinol group and the TPH-M group, or between the alloputinol group and the TPH group. Compared to the model control group, the TPH-D treatment seemed to cause insignificant (P > 0.05) decrease of the XO mRNA expression, indicating that TPH-D had minimal influence on the XO mRNA expression in hyperuricemia rats.
In the present study, the reduction of XO mRNA expression was also associated with a significantly XO activity decrease, suggesting that decreased XO mRNA expression could be one possible mechanism for liver XO inhibition in hyperuricemia rats. The similar reduction of XO mRNA expression and inhibition of XO activity in various traditional Chinese medicines were found (Gao et al., 2010) . Additionally, TPH-D and TPH exhibited different effects on XO mRNA expression, possibly due to their differing sensibility and accessibility to various intracellular peptidases. TPH-M treatment would reduce mRNA expression to greater extent than TPH, suggesting the composition and other physicochemical characteristics of TPH changed after the Maillard reaction. Such changes likely allowed the components in TPH-M to interact with promoters and/or induce inhibitors of mRNA expression.
Effect of TPH, TPH-D, TPH-M on serum uric acid levels of rats
There was no significantly (P > 0.05) different body weight between trial groups and normal groups (data not show), indicating that TPH, TPH-D and TPH-M would not have negative effect on hyperuricemia rats. The serum uric acids levels of normal rats and hyperuricemia rats treated with or without samples at 80 mg kg À1 (THP, THP-D and THP-M, respectively) for 30 days were analysed, and the results are shown in Fig. 3 . The serum uric acid index of normal rats was 110.82 lmol L À1 , and significantly (P < 0.05) increased to 338.08 lmol L À1 when treated by potassium oxonate. Administration of allopurinol at 25 mg kg À1 could largely reduce uric acid levels of hyperuricemia rats (131.16 lmol L À1 ). Similarity, the hyperuricemia rats treated by THP, THP-D and THP-M all showed lower (P < 0.05) serum uric acid levels than model rats. However, different serum uric acid levels were observed among the three trial groups, there were no significant (P > 0.05) difference between THP group (273.55 lmol L À1 ) and THP-D group (266.54 lmol L À1 ), while THP-M group (299.50 lmol L À1 ) showed much higher serum uric acid levels. It indicated that administration of TPH, THP-D and THP-M had significant antihyperuricemic effect.
In summary, TPH-M was generally the most effective to provide the inhibition of XO activity in vitro and in vivo, and XO mRNA expression lowing effect, irrespective of the lowest antihyperuricemic activity. TPH and TPH-D exhibited a lower XO inhibitory activity in vitro and in vitro compared to TPH-M, and low suppressive effect on XO mRNA expression, but an excellent antihyperuricemic effect on hyperuricemia rats. It was hypothesis that the overall antihyperuricemic effect of TPH, TPH-D and TPH-M was determined by multiple influencing factors (not just XO activity and XO mRNA expression). Previously published studies already demonstrated that the patients with hyperuricemia are often associated with a risk of oxidative stress-induced renal damage particularly in liver and kidney (Smith et al., 2010) . TPH used in this present study possessed high antioxidant activity, such as TPH at 10 mg mL À1 had an O 2Àṙ adical scavenging activity of 47.98%, which could reduce the oxidative damage of the kidney and even recover the kidney's function to modulate the level of serum uric acid. Accumulating studies indicated that hyperuricemia would likely lead to the development and incidence of chronic nephritis and renal dysfunction (Borghi et al., 2015) . Our recent studies revealed a tiny decrease in serum creatinine and urea nitrogen levels accompany by nephroprotective effect in hyperuricemia rats after oral administration with TPH, TPH-D or TPH-M (as showed in Fig. S1 ). These suggested that TPH, TPH-D and TPH-M could recondition renal physiology and then increase the excretion of uric acid. Walnut protein hydrolysates (Li et al., 2018) and Epigallocatechin-3-gallate (Zhu et al., 2017) also exhibited effective protective function in the improvement of renal failure.
Conclusion
In present study, results revealed that although TPH exhibited no significantly (P > 0.05) different XO inhibitory activity than its in vitro simulated GI digestion Each column height and error bar represents the mean value and standard deviation of the data, respectively, from twelve rats. Columns marked with different letters indicate significant differences (P < 0.05). TPH, tuna protein hydrolysate; TPH-D, TPH, after being subject to in vitro digestion; TPH-M, TPH after being subject to the Maillard reaction.
(TPH-D), different XO inhibitory activity and XO mRNA expression were observed in hyperuricemia rats treated by TPH and TPH-D. Moreover, TPH-M showed higher XO inhibitory activity in vitro and in vivo, but lower serum-uric-acid-lowering effect was observed. This indicated that Maillard reaction might have negative effect on the antihyperuricemic activity of TPH in vivo. In conclusion, administration of TPH, TPH-D and TPH-M could moderate hyperuricemia in rats via inhibiting XO activity, down-regulating XO mRNA expression, and also governing by other regulation pathway. The result suggested that TPH is a potential agent against hyperuricemic. Further work would direct towards the structure of functional peptides with the inhibition of XO activity and associated mechanism of their action as agents.
